4.6 Article

M-leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator

期刊

ACTA NEUROPATHOLOGICA
卷 129, 期 5, 页码 653-667

出版社

SPRINGER
DOI: 10.1007/s00401-015-1404-5

关键词

Leprosy; Complement; Neuropathy; Therapy

资金

  1. Leprosy Foundation of the Netherlands [701.03.08]

向作者/读者索取更多资源

Peripheral nerve damage is the hallmark of leprosy pathology but its etiology is unclear. We previously identified the membrane attack complex (MAC) of the complement system as a key determinant of post-traumatic nerve damage and demonstrated that its inhibition is neuroprotective. Here, we determined the contribution of the MAC to nerve damage caused by Mycobacterium leprae and its components in mouse. Furthermore, we studied the association between MAC and the key M. leprae component lipoarabinomannan (LAM) in nerve biopsies of leprosy patients. Intraneural injections of M. leprae sonicate induced MAC deposition and pathological changes in the mouse nerve, whereas MAC inhibition preserved myelin and axons. Complement activation occurred mainly via the lectin pathway and the principal activator was LAM. In leprosy nerves, the extent of LAM and MAC immunoreactivity was robust and significantly higher in multibacillary compared to paucibacillary donors (p = 0.01 and p = 0.001, respectively), with a highly significant association between LAM and MAC in the diseased samples (r = 0.9601, p = 0.0001). Further, MAC co-localized with LAM on axons, pointing to a role for this M. leprae antigen in complement activation and nerve damage in leprosy. Our findings demonstrate that MAC contributes to nerve damage in a model of M. leprae-induced nerve injury and its inhibition is neuroprotective. In addition, our data identified LAM as the key pathogen associated molecule that activates complement and causes nerve damage. Taken together our data imply an important role of complement in nerve damage in leprosy and may inform the development of novel therapeutics for patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Surgery

Whole-exome Sequencing Identifies SLC52A1 and ZNF106 Variants as Novel Genetic Risk Factors for (Early) Multiple-organ Failure in Acute Pancreatitis

Fons F. van den Berg, Yama Issa, Jeroen P. Vreijling, Markus M. Lerch, Frank Ulrich Weiss, Marc G. Besselink, Frank Baas, Marja A. Boermeester, Hjalmar C. van Santvoort

Summary: Genomic sequencing revealed that ZNF106 and SLC52A1 may be associated with the development of early multiple organ failure in acute pancreatitis.

ANNALS OF SURGERY (2022)

Article Immunology

Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex

Heidi Gytz Olesen, Iliana Michailidou, Wioleta M. Zelek, Jeroen Vreijling, Patrick Ruizendaal, Ferry de Klein, J. Arnoud Marquart, Thomas B. Kuipers, Hailiang Mei, Yuchun Zhang, Muhammad Ahasan, Krista K. Johnson, Yi Wang, B. Paul Morgan, Marcus van Dijk, Kees Fluiter, Gregers Rom Andersen, Frank Baas

Summary: Damage and disease of nerves activate the complement system, leading to the formation of the membrane attack complex (MAC) and delaying nerve regeneration. By studying the complement component C6, researchers have developed a novel therapeutic monoclonal antibody, CP010, that prevents MAC formation and shows potential therapeutic use in neurological diseases. The antibody blocks the interaction between C6 and C5/C5b and demonstrates efficacy in preventing disease and relapse in animal models.

JOURNAL OF INNATE IMMUNITY (2023)

Article Clinical Neurology

Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes

Remco J. Hack, Minne N. Cerfontaine, Gido Gravesteijn, Stephan Tap, Anne Hafkemeijer, Jeroen van der Grond, Marie-Noelle Witjes-Ane, Frank Baas, Julie W. Rutten, Saskia A. J. Lesnik Oberstein

Summary: This study is the first genotype-driven, large prospective CADASIL cohort study, and the results indicate that the NOTCH3 EGFr group is the most important modifier in CADASIL disease. Male sex and hypertension also have a significant impact on clinical outcomes and neuroimaging markers.

STROKE (2022)

Article Immunology

Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19

Matthew K. Siggins, Kate Davies, Rosie Fellows, Ryan S. Thwaites, J. Kenneth Baillie, Malcolm G. Semple, Peter J. M. Openshaw, Wioleta M. Zelek, Claire L. Harris, B. Paul Morgan

Summary: This study is the largest comprehensive study of complement in COVID-19 to date. It demonstrates the important role of complement in the immunopathogenesis of COVID-19. Early-onset, uncontrolled activation of complement is a ubiquitous feature of COVID-19, further exacerbated in severe cases. These findings provide novel insights into the immunopathogenesis of COVID-19 and inform strategies for therapeutic intervention.

IMMUNOLOGY (2023)

Article Biochemistry & Molecular Biology

Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice

Florine Seidel, Robert Kleemann, Wim van Duyvenvoorde, Nikki van Trigt, Nanda Keijzer, Sandra van der Kooij, Cees van Kooten, Lars Verschuren, Aswin Menke, Amanda J. Kiliaan, Johnathan Winter, Timothy R. Hughes, B. Paul Morgan, Frank Baas, Kees Fluiter, Martine C. Morrison

Summary: Complement inhibition with an anti-C5 antibody is not effective in reducing the progression of NASH but is beneficial in established atherosclerosis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Clinical Neurology

Tackling Neuroinflammation After Traumatic Brain Injury: Complement Inhibition as a Therapy for Secondary Injury

Inge A. M. van Erp, Iliana Michailidou, Thomas A. van Essen, Mathieu van der Jagt, Wouter Moojen, Wilco C. Peul, Frank Baas, Kees Fluiter

Summary: Traumatic brain injury is a major cause of death and neurofunctional impairment, with neuroinflammation playing a crucial role in secondary brain injury. Attenuating the inflammatory response is a potential therapeutic goal, but non-selective attenuation in the early phase may have detrimental effects. The complement system is involved in the pathophysiology of neuroinflammation after brain injury, suggesting it as a target for therapy.

NEUROTHERAPEUTICS (2023)

Article Clinical Neurology

Dendritic spine loss in epileptogenic Type II focal cortical dysplasia: Role of enhanced classical complement pathway activation

Laura Rossini, Dalia De Santis, Erica Cecchini, Cinzia Cagnoli, Emanuela Maderna, Daniele Cartelli, Bryan Paul Morgan, Megan Torvell, Roberto Spreafico, Roberta di Giacomo, Laura Tassi, Marco de Curtis, Rita Garbelli

Summary: Dendritic spines are crucial for excitatory glutamatergic synapses. The study explores the role of complement components C1q and C3 in synaptic pruning imbalance in Type II focal cortical dysplasia (FCD). The findings provide valuable insights into the understanding and treatment of diseases related to Type II FCD.

BRAIN PATHOLOGY (2023)

Article Immunology

Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity

L. M. Goff, K. Davies, W. M. Zelek, E. Kodosaki, O. Hakim, S. Lockhart, S. O'Rahilly, B. P. Morgan

Summary: Poor metabolic health and obesity in Black African populations contribute to increased susceptibility to disease, including COVID-19. Complement dysregulation has been linked to metabolic health and implicated as a driver of pathology; however, ethnic differences in complement have not been explored.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2023)

Article Neurosciences

Complement receptor 1 is expressed on brain cells and in the human brain

Nikoleta Daskoulidou, Bethany Shaw, Megan Torvell, Lewis Watkins, Emma L. Cope, Sarah M. Carpanini, Nicholas D. Allen, B. Paul Morgan

Summary: Genome wide association studies have found that Complement receptor 1 (CR1) is associated with increased risk for Alzheimer's disease (AD). However, the expression and role of CR1 in the brain are poorly understood. This study used various methods to demonstrate that CR1 is indeed expressed in human microglia and astrocytes in the brain, and that its expression is significantly increased in AD. These findings support the hypothesis that CR1 variants affect AD risk through their impact on glial functions.
Article Immunology

Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model

Naoki Kamegai, Hangsoo Kim, Yasuhiro Suzuki, Sosuke Fukui, Hiroshi Kojima, Shoichi Maruyama, B. Paul Morgan, Wioleta Milena Zelek, Masashi Mizuno

Summary: In this study, we used a novel mAb 2H2 to investigate the role of the complement terminal pathway in peritoneal injuries associated with peritoneal dialysis. The results showed that blocking the assembly of the membrane attack complex (MAC) with mAb 2H2 reduced peritoneal thickness and inflammation in a dose-dependent manner. This indicates that targeting MAC might be an effective therapy for preventing peritoneal injuries in humans.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2023)

Article Neurosciences

Ldlr-/-.Leiden mice develop neurodegeneration, age-dependent astrogliosis and obesity-induced changes in microglia immunophenotype which are partly reversed by complement component 5 neutralizing antibody

Florine Seidel, Kees Fluiter, Robert Kleemann, Nicole Worms, Anita van Nieuwkoop, Martien P. M. Caspers, Nikolaos Grigoriadis, Amanda J. J. Kiliaan, Frank Baas, Iliana Michailidou, Martine C. C. Morrison

Summary: This study used the Ldlr-/-.Leiden mouse model to investigate brain pathology in the context of obesity and vascular dysfunction. The results showed neurodegeneration and astrocytosis in the brains of the mice, as well as altered microglial immunophenotype and molecular pathways. Treatment with an anti-complement therapy partially restored the effects of high-fat diet on the brain, suggesting its potential therapeutic value against obesity-induced neuroinflammation.

FRONTIERS IN CELLULAR NEUROSCIENCE (2023)

Article Clinical Neurology

Tackling Neuroinflammation After Traumatic Brain Injury: Complement Inhibition as a Therapy for Secondary Injury

Inge A. M. van Erp, Iliana Michailidou, Thomas A. van Essen, Mathieu van der Jagt, Wouter Moojen, Wilco C. Peul, Frank Baas, Kees Fluiter

Summary: Traumatic brain injury (TBI) is a major cause of death and disability, and neuroinflammation is a key driver of secondary brain injury after TBI. This review examines the pathophysiology of neuroinflammation and the clinical trials conducted to reduce it. The complement system and its interaction with the coagulation system play an important role in the development of secondary brain injury, making them potential targets for therapy. However, more research is needed to explore specific pathways for pharmacological interventions.

NEUROTHERAPEUTICS (2023)

Meeting Abstract Gastroenterology & Hepatology

THERAPEUTIC INHIBITION OF COMPLEMENT COMPONENT 5 DOES NOT REDUCE NASH PROGRESSION BUT DOES ATTENUATE ATHEROSCLEROSIS DEVELOPMENT IN LDLR--/--.LEIDEN MICE

Florine Seidel, Robert Kleemann, Wim Van Duyvenvoorde, Nanda Keijzer, Nikki Van Trigt, Sandra Van der Kooij, Cees Van Kooten, Lars Verschuren, Aswin L. Menke, Amanda Kiliaan, Johnathan Winter, Timothy Hughes, Paul Morgan, Frank Baas, Kees Fluiter, Martine Morrison

HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Therapeutic inhibition of complement component 5 does not reduce NASH progression but does attenuate atherosclerosis development in Ldlr-/-.Leiden mice

Florine Seidel, Robert Kleemann, Wim van Duyvenvoorde, Nikki van Trigt, Nanda Keijzer, Sandra van der Kooij, Cees van Kooten, Lars Verschuren, Aswin L. Menke, Johnathan Winter, Timothy Hughes, Paul Morgan, Frank Baas, Kees Fluiter, Martine C. Morrison, Amanda Kiliaan

JOURNAL OF HEPATOLOGY (2022)

暂无数据